dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 19, 2026

Defense Stock Face-Off: Lockheed Martin vs. Howmet Aerospace -- Which Is the Better Buy Right Now?

View original at nasdaq.com
Defense Stock Face-Off: Lockheed Martin vs. Howmet Aerospace -- Which Is the Better Buy Right Now? Key Points Lockheed Martin and Howmet Aerospace benefit from increased defense spending…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Howmet Aerospace is trading at more than 54 times forward earnings estimates, more than twice Lockheed's forward P/E ratio of 20.6, meaning much of Howmet's growth is already priced in

    60% confidence
  • Lockheed Martin's position as lead contractor for F-35 and major missile programs ensures steady cash flow largely insulated from traditional economic recessions

    60% confidence
  • The war in Iran will push Howmet's likely growth higher in 2026

    60% confidence
  • Lockheed Martin is a better buy than Howmet Aerospace due to steady income production, huge backlog, and greater diversity

    60% confidence
  • The Motley Fool Stock Advisor identified 10 best stocks for investors to buy now, and Lockheed Martin was not one of them

    60% confidence

Data points we hold from this source

Lockheed Martin Corporation · forward pe ratio20.6 ratio
Lockheed Martin Corporation · backlog194 USD
Lockheed Martin Corporation · quarterly dividend3.45 USD
Lockheed Martin Corporation · eps21.49 USD
Lockheed Martin Corporation · consecutive dividend increases23 years
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,997
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,997 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Defense Stock Face-Off: Lockheed Martin vs. Howmet Aerospace -- Which Is the Better Buy Right Now?: Source | Via News | fr.via.news